Investment accounts
Adult accounts
Child accounts
Choosing Fidelity
Choosing Fidelity
Why invest with us Current offers Fees and charges Open an account Transfer investments
Financial advice & support
Fidelity’s Services
Fidelity’s Services
Financial advice Retirement Wealth Management Investor Centre (London) Bereavement
Guidance and tools
Guidance and tools
Choosing investments Choosing accounts ISA calculator Retirement calculators
Share dealing
Choose your shares
Tools and information
Tools and information
Share prices and markets Chart and compare shares Stock market news Shareholder perks IPOs and placings
Pensions & retirement
Pensions, tax & tools
Saving for retirement
Approaching / In retirement
Approaching / In retirement
Speak to a specialist Creating a retirement plan Taking tax-free cash Pension drawdown Annuities Investing in retirement Investment Pathways
Europe close: Stocks little changed in calm trading
(Sharecast News) - European shares ended Monday on a mixed note with US markets closed for the Presidents Day holiday. Investors also opted to sit on their hands ahead of the release of the minutes of the Federal Reserve's last policy meeting, on Wednesday, and potentially key euro area quarterly wage survey data on Thursday.
The pan-European Stoxx 600 index edged up 0.16% to 492.39, alongside a 0.18% dip to 31,676.05 on the FTSE Mib and a flat close on the Cac-40.
Euro/dollar, German Bunds and Brent crude oil futures were little changed alongside.
In the background, shares in Shanghai rose 1.6% as traders returned from the Lunar New Year holidays with sentiment boosted by upbeat travel data - although market commentary around the gains was rather downbeat.
In equity news, Currys was at the centre of a potential takeover battle between US private equity outfit Elliott and Chinese ecommerce giant JD.com. Currys management said it had already rejected a £700m approach from the former, claiming it "significantly undervalued" the chain. Shares in the chain surged by 35%.
Shares in AstraZeneca rose after the US Food and Drug Administration approved use of the company's blockbuster cancer drug Tagrisso with chemotherapy to treat a type of lung cancer.
Meantime, shares of German IT company Bechtle dropped sharply after Barclays rated the stock as 'underweight'.
Share this article
Related Sharecast Articles
Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.
Award-winning online share dealing
Search, compare and select from thousands of shares.
Expert insights into investing your money
Our team of experts explore the world of share dealing.
Policies and important information
Accessibility | Conflicts of interest statement | Consumer Duty Target Market | Consumer Duty Value Assessment Statement | Cookie policy | Diversity and Inclusion | Doing Business with Fidelity | Fidelity gender pay report | Investing in Fidelity funds | Legal information | Modern slavery | Mutual respect policy | Privacy statement | Remuneration policy | Security | Statutory and Regulatory disclosures | Whistleblowing policy
Please remember that past performance is not necessarily a guide to future performance, the performance of investments is not guaranteed, and the value of your investments can go down as well as up, so you may get back less than you invest. When investments have particular tax features, these will depend on your personal circumstances and tax rules may change in the future. This website does not contain any personal recommendations for a particular course of action, service or product. You should regularly review your investment objectives and choices and, if you are unsure whether an investment is suitable for you, you should contact an authorised financial adviser. Before opening an account, please read the ‘Doing Business with Fidelity’ document which incorporates our client terms. Prior to investing into a fund, please read the relevant key information document which contains important information about the fund.
This website is issued by Financial Administration Services Limited, which is authorised and regulated by the Financial Conduct Authority (FCA) (FCA Register number 122169) and registered in England and Wales under company number 1629709 whose registered address is Beech Gate, Millfield Lane, Lower Kingswood, Tadworth, Surrey, KT20 6RP.
